← Drug database

Clopidogrel BGR (previously Zylagren) (clopidogrel)

Generic
Region
🇪🇺 EU
Active substance
clopidogrel
Company
Biogaran
Status
Authorised
Therapeutic area
Peripheral Vascular Diseases; Stroke; Myocardial Infarction
EU approval
Mon 21 Sep 2009
Designations
Generic
Application
EMEA/H/C/001138
ATC
B01AC03
Official record
www.ema.europa.eu

Indication

Prevention of atherothrombotic events Clopidogrel is indicated in: Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Clopidogrel BGR (previously Zylagren)

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.